Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2018

18.01.2018 | Preclinical study

Impact of an embedded genetic counselor on breast cancer treatment

verfasst von: Holly J. Pederson, Najaah Hussain, Ryan Noss, Courtney Yanda, Colin O’Rourke, Charis Eng, Stephen R. Grobmyer

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

We predicted that embedding a genetic counselor within our breast practice would improve identification of high-risk individuals, timeliness of care, and appropriateness of surgical decision making. The aim of this study is to compare cancer care between 2012 and 2014, prior to embedding a genetic counselor in the breast center and following the intervention, respectively.

Methods

A retrospective review of patients diagnosed with breast cancer in 2012 (n = 471) and 2014 (n = 440) was performed to assess patterns of medical genetics referral, compliance with referral, genetic testing findings, and impact on treatment.

Results

Between 2012 and 2014, patients were 49% more likely to be referred to genetics, 66% more likely to follow through with their genetic counseling appointment, experienced a 73% reduction in wait times to genetic counseling visits and 69% more likely to have genetic testing results prior to surgery. Notably, while the number of genetic mutations identified was in the expected range over both time periods (9% of those tested in 2012 vs. 6.6% of those tested in 2014), there was a 31% reduction in time to treatment in 2014 vs. 2012.

Conclusion

Awareness of germline genetic mutations is critical in surgical decision making for newly diagnosed breast cancer patients. Having an experienced genetics specialist on site in a busy surgical breast clinic allows for timely access to genetic counseling and testing, and may have influenced time to treatment in our institution.
Literatur
1.
Zurück zum Zitat Buys SS, Sandbach JF, Gammon A et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123:1721–1730CrossRefPubMed Buys SS, Sandbach JF, Gammon A et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123:1721–1730CrossRefPubMed
2.
Zurück zum Zitat Couch FJ, Hart SN, Sharma P et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304–311CrossRefPubMed Couch FJ, Hart SN, Sharma P et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304–311CrossRefPubMed
3.
Zurück zum Zitat Kurian AW, Hare EE, Mills MA et al (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001–2009CrossRefPubMedPubMedCentral Kurian AW, Hare EE, Mills MA et al (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001–2009CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33CrossRefPubMed Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33CrossRefPubMed
5.
Zurück zum Zitat Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34:1460–1468CrossRefPubMedPubMedCentral Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34:1460–1468CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Yurgelun MB, Allen B, Kaldate RR et al (2015) Identification of a variety of mutations in cancer predisposition genes in patients with suspected lynch syndrome. Gastroenterology 149(604–13):e20 Yurgelun MB, Allen B, Kaldate RR et al (2015) Identification of a variety of mutations in cancer predisposition genes in patients with suspected lynch syndrome. Gastroenterology 149(604–13):e20
7.
Zurück zum Zitat NCCN Guidelines 1. 2018 genetic/familial risk assessment: breast and ovarian. 2017 NCCN Guidelines 1. 2018 genetic/familial risk assessment: breast and ovarian. 2017
8.
Zurück zum Zitat Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J (2014) Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol 134:326–330CrossRefPubMed Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J (2014) Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol 134:326–330CrossRefPubMed
9.
Zurück zum Zitat Pennington KP, Walsh T, Harrell MI et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764–775CrossRefPubMed Pennington KP, Walsh T, Harrell MI et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764–775CrossRefPubMed
10.
Zurück zum Zitat Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed
11.
Zurück zum Zitat Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379CrossRefPubMed Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379CrossRefPubMed
12.
Zurück zum Zitat Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416CrossRefPubMed Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416CrossRefPubMed
13.
Zurück zum Zitat Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138:1323–1328; discussion 9 Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138:1323–1328; discussion 9
14.
Zurück zum Zitat Metcalfe K, Gershman S, Ghadirian P et al (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226CrossRefPubMedPubMedCentral Metcalfe K, Gershman S, Ghadirian P et al (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Eichmeyer JN, Burnham C, Sproat P, Tivis R, Beck TM (2014) The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review. J Genet Couns 23:323–329CrossRefPubMed Eichmeyer JN, Burnham C, Sproat P, Tivis R, Beck TM (2014) The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review. J Genet Couns 23:323–329CrossRefPubMed
16.
Zurück zum Zitat Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21:151–161CrossRefPubMed Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21:151–161CrossRefPubMed
17.
Zurück zum Zitat Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology Policy Statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 33:3660–3667CrossRefPubMed Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology Policy Statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 33:3660–3667CrossRefPubMed
18.
Zurück zum Zitat Surgeons ACo. (2014) NAPBC standards manual, pp 1–78 Surgeons ACo. (2014) NAPBC standards manual, pp 1–78
19.
Zurück zum Zitat Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A (2013) Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer 23:431–436CrossRefPubMed Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A (2013) Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer 23:431–436CrossRefPubMed
20.
Zurück zum Zitat Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40:61–66CrossRefPubMed Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40:61–66CrossRefPubMed
21.
Zurück zum Zitat Brierley KL, Campfield D, Ducaine W et al (2010) Errors in delivery of cancer genetics services: implications for practice. Conn Med 74:413–423PubMed Brierley KL, Campfield D, Ducaine W et al (2010) Errors in delivery of cancer genetics services: implications for practice. Conn Med 74:413–423PubMed
22.
Zurück zum Zitat Freedman AN, Wideroff L, Olson L et al (2003) US physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 120A:63–71CrossRefPubMed Freedman AN, Wideroff L, Olson L et al (2003) US physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 120A:63–71CrossRefPubMed
23.
Zurück zum Zitat Whitworth P, Beitsch P, Arnell C et al (2017) Impact of payer constraints on access to genetic testing. J Oncol Pract 13:e47–e56CrossRefPubMed Whitworth P, Beitsch P, Arnell C et al (2017) Impact of payer constraints on access to genetic testing. J Oncol Pract 13:e47–e56CrossRefPubMed
24.
Zurück zum Zitat Kurian AW, Li Y, Hamilton AS et al (2017) Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol 35:2232–2239CrossRefPubMed Kurian AW, Li Y, Hamilton AS et al (2017) Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol 35:2232–2239CrossRefPubMed
25.
Metadaten
Titel
Impact of an embedded genetic counselor on breast cancer treatment
verfasst von
Holly J. Pederson
Najaah Hussain
Ryan Noss
Courtney Yanda
Colin O’Rourke
Charis Eng
Stephen R. Grobmyer
Publikationsdatum
18.01.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4643-4

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research and Treatment 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.